LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LEMAITRE VASCULAR director Bridget A. Ross reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised stock options to acquire a total of 5,044 shares of Common Stock, including 1,600 shares at an exercise price of $47.19 per share and 3,444 shares at $48.60 per share.
On the same date, she completed an open‑market sale of 5,044 Common Stock shares at a weighted average price of $111.0956 per share, executed in multiple trades ranging from $111.00 to $111.30. Following these transactions, she directly owns 3,942 Common Stock shares, and the reported options tied to these exercises are fully vested and, after exercise, no longer outstanding.
LeMaitre Vascular director Lawrence J. Jasinski reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 3,943 shares of common stock in an open-market sale at $110.00 per share, leaving him with 4,714 directly held shares afterward.
On the same date, he exercised stock options to acquire a total of 2,858 common shares at exercise prices of $101.12, $54.65, and $47.19 per share. Related option entries show remaining option positions in multiple grants following these exercises. Overall, the filing reflects a combination of option exercises and a net sale of shares.
LeMaitre Vascular Inc. officer Trent G. Kamke's Form 144 reports a proposed sale of 2,928 common shares, with an aggregate market value of $313,286.92 and an approximate sale date of May 8, 2026. It also lists Kamke's sales during the past three months: 2,625 shares on March 11, 2026, for gross proceeds of $284,812.50, and 1,044 shares on February 27, 2026, for gross proceeds of $115,142.76.
LeMaitre Vascular, Inc. (LMAT) reports that director Lawrence J. Jasinski filed a notice of a proposed sale of 3,943 common shares, with an aggregate market value of $433,730 and an approximate sale date of May 7, 2026. The notice names Morgan Stanley Smith Barney LLC as the broker. The acquisition table lists 2,858 shares from a stock option exercise dated May 7, 2026, as well as performance-share and restricted-stock acquisitions.
LeMaitre Vascular, Inc. reported solid first‑quarter 2026 growth with higher sales, margins, and earnings. Net sales rose to $66.6 million, up 11% from 2025, driven by grafts, valvulotomes, and shunts across all regions. Gross profit increased to $48.4 million and gross margin improved to 72.7%, helped by price increases, manufacturing efficiencies, and a more profitable product mix.
Net income grew to $15.7 million, up from $11.0 million, with diluted EPS at $0.68. The company generated $15.1 million of operating cash flow, ending the quarter with $26.9 million in cash and $340.4 million in short‑term marketable securities, alongside $172.5 million of 2.50% convertible senior notes due 2030.
LeMaitre increased its quarterly dividend to $0.25 per share and authorized a $100 million share repurchase program, while continuing to invest in global sales expansion, ERP implementation, and facility leases. Biologics represented 53% of sales, and international markets contributed 44% of net sales, aided by a weaker U.S. dollar and recent regulatory approvals.
LeMaitre Vascular, Inc. reported strong preliminary Q1 2026 results with net sales of $66.6M, up from $59.9M, driven by 11% sales growth and broad strength across products and regions. Artegraft sales grew 36% worldwide, while grafts, valvulotomes, and carotid shunts each set record sales.
Gross margin reached 72.7%, up 350 basis points, and operating income rose to roughly $17.8M, a 41% increase. Diluted EPS grew 42% in Q1. Management’s guidance implies full-year 2026 sales growth of 12% and adjusted EPS growth of 26%, with Q2 sales expected around $71.5M at the midpoint.
The board approved a quarterly dividend of $0.25 per share payable on June 4, 2026, and authorized a share repurchase program of up to $100M through February 18, 2027. The company also highlighted non-GAAP metrics such as adjusted EBITDA and organic sales growth.
LeMaitre Vascular director Joseph P. Pellegrino Jr. exercised stock options to acquire 2,941 shares of Common Stock at $35.48 per share. These shares came from a fully vested option that was exercised in full, leaving no remaining derivative position from this grant. Following the transaction, he directly owns 15,021 Common shares, making this a routine compensation-related option exercise rather than an open-market purchase or sale.
LeMaitre Vascular, Inc. is asking stockholders to vote at its 2026 annual meeting on June 2, 2026, in Burlington, Massachusetts. Investors will elect two Class II directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify Grant Thornton LLP as auditor for 2026.
The proxy highlights a seven‑member, largely independent board with extensive medical device and financial expertise, and describes governance practices such as a director resignation policy, clawback policy, insider trading restrictions, and board‑level risk oversight. It also discloses major shareholders and 2025 executive pay structure, which ties a significant portion of compensation to financial and operational performance.
LeMaitre Vascular, Inc. reports upcoming changes to its Board of Directors tied to the 2026 Annual Meeting of Stockholders on June 2, 2026. Bridget Ross, a Class II director, has informed the Board she will not stand for re-election and will serve until her current term ends at that meeting. The company states her decision is not due to any disagreement regarding operations, policies, or practices.
To rebalance the staggered board, the Board has nominated David B. Roberts to stand for election as a Class II director at the same meeting. In connection with this nomination, Mr. Roberts has indicated he will resign as a Class I director at the conclusion of the meeting, contingent on his election as a Class II director. After these changes, the Board will have seven members instead of eight, structured as two Class I directors, two Class II directors, and three Class III directors, consistent with the company’s charter and by-law provisions allowing the Board to set its own size.